A Unique Approach to the Delivery of Rapid Onset Opioids
Sponsored by ProStrakan, Inc.
This activity is not certified for credit.
Date
Friday, September 9, 2011
Start Time
8:30 am
End Time
9:30 am
Room
Mont-Royal Ballroom
Level 4
Program Description
This program introduces a unique transmucosal fentanyl that has been shown to be effective for treating breakthrough cancer pain in opioid-tolerant patients. Patient cases will be presented both to highlight the safety and tolerability of sublingual fentanyl as well as to give healthcare providers insight into how this medication can be used effectively and appropriately in their own practice to manage breakthrough pain in patients with cancer.
Faculty
Srinivas Nalamachu, MD
James Rho, MD
Web site
www.BreakthroughPainPDM.com
Contact Name
Desiree Hollandsworth
Contact Phone
484-947-5003 ext. 127
- Pathophysiology of Pain: Mechanisms and Manifestations
- Responsible Opioid Prescribing in the Era of REMS
- Risk Mitigation in Reality: Best Practices from a Transmucosal Fentanyl REMS
- Persistent and Breakthrough Cancer Pain
- Chronic Pain: Best Practices in Interdisciplinary Multimodal Management
